Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Chemotherapy for High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
NCT04628767Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2021
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab in upper tract urothelial carcinoma (UTUC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Event-free survival up to 5 years and Pathologic complete response. Started Nov 2021; status: recruiting.
02
Drugs
durvalumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT04628767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04628767.